ADMP Adamis Pharmaceuticals Corporation Stock Quote

ADMP [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	1.06%	Shs Outstand	148.89M	Perf Week	16.04%
Market Cap	178.30M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	0.00%	Shs Float	147.89M	Perf Month	11.82%
Income	-49.40M	PEG	-	EPS next Q	-0.06	Inst Own	10.80%	Short Float	6.48%	Perf Quarter	21.78%
Sales	16.50M	P/S	10.81	EPS this Y	-23.30%	Inst Trans	-	Short Ratio	3.02	Perf Half Y	81.55%
Book/sh	0.04	P/B	30.75	EPS next Y	13.00%	ROA	-123.70%	Target Price	-	Perf Year	33.13%
Cash/sh	0.05	P/C	25.84	EPS next 5Y	-	ROE	-226.50%	52W Range	0.38 - 2.34	Perf YTD	153.56%
Dividend	-	P/FCF	-	EPS past 5Y	9.00%	ROI	-565.70%	52W High	-47.44%	Beta	1.30
Dividend %	-	Quick Ratio	0.50	Sales past 5Y	-	Gross Margin	9.90%	52W Low	227.56%	ATR	0.08
Employees	116	Current Ratio	0.60	Sales Q/Q	-34.50%	Oper. Margin	-	RSI (14)	73.79	Volatility	9.37% 6.10%
Optionable	Yes	Debt/Eq	1.51	EPS Q/Q	-244.90%	Profit Margin	-	Rel Volume	47.33	Prev Close	1.13
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Jul 19 AMC	Payout	-	Avg Volume	3.17M	Price	1.23
Recom	3.00	SMA20	18.66%	SMA50	16.89%	SMA200	22.00%	Volume	149,977,766	Change	8.85%

May-13-20

Upgrade

Maxim Group

Hold → Buy

$1.50

Feb-27-20

Downgrade

Dawson James

Buy → Neutral

Nov-26-19

Downgrade

Raymond James

Outperform → Mkt Perform

Jul-16-19

Downgrade

B. Riley FBR

Neutral → Sell

$1.90 → $1.10

Nov-12-18

Downgrade

B. Riley FBR

Buy → Neutral

$7.50 → $2.50

May-11-18

Reiterated

Maxim Group

Buy

$5 → $10

Mar-23-18

Reiterated

B. Riley FBR, Inc.

Buy

$6.25 → $7.50

Dec-05-17

Reiterated

Maxim Group

Buy

$13 → $14

Oct-04-17

Resumed

B. Riley & Co.

Buy

$9.50

Jul-21-16

Reiterated

Maxim Group

Buy

$17 → $10

Dec-01-15

Initiated

Maxim Group

Buy

$16

May-29-15

Initiated

Mizuho

Buy

$10

Jan-28-14

Initiated

CRT Capital

Buy

$15

Oct-18-21 08:55AM	Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval MarketWatch +8.85%
07:58AM	Adamis Pharma Stock Jumps as FDA Clears Opioid-Overdose Treatment TheStreet.com
07:30AM	Adamis Receives FDA Approval for ZIMHI GlobeNewswire
Oct-11-21 05:44PM	East Bay Parkinson's drug maker to be swallowed up in potential $450M deal American City Business Journals
Oct-04-21 07:30AM	Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors GlobeNewswire
Sep-03-21 12:12PM	Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study Zacks
Sep-02-21 10:56AM	Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing Benzinga
07:30AM	Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19 GlobeNewswire
Aug-24-21 04:05PM	Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events GlobeNewswire
01:14PM	Immunology Journal Publishes Data For Adamis' COVID-19 Candidate Benzinga
07:30AM	Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patients Cells GlobeNewswire
Aug-19-21 07:30AM	Adamis Highlights National Institutes of Health (NIH) Article Entitled, Tempol: A Potential Home Treatment for COVID-19 GlobeNewswire
Aug-04-21 04:05PM	Adamis Announces Agreement to Sell Portion of US Compounding Business GlobeNewswire
Jul-19-21 04:05PM	Adamis Announces Results of 2021 Annual Meeting of Stockholders Business Wire +12.77%
Jul-13-21 08:00AM	Adamis Urges Stockholders to Vote to Reelect the Companys Board of Directors at Upcoming Annual Meeting on Friday, July 16th Business Wire
Jul-01-21 08:00AM	Adamis Sends Letter to Stockholders to Address Jerald A. Hammanns Costly, Distracting and Misguided Campaign Business Wire
Jun-28-21 07:00AM	Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19 Business Wire
Jun-18-21 08:32AM	Are Options Traders Betting on a Big Move in Adamis Pharmaceuticals (ADMP) Stock? Zacks -6.36%
Jun-14-21 09:00AM	Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders Business Wire
Jun-13-21 02:11PM	Is Adamis Pharmaceuticals Corporation (ADMP) Going to Burn These Hedge Funds? Insider Monkey
Jun-11-21 07:30AM	Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19 GlobeNewswire
Jun-09-21 07:30AM	Adamis Provides Update on ZIMHI GlobeNewswire +6.93%
Jun-07-21 09:51AM	Adamis Pharma Stock Jumps as NIH Sees Promise in Tempol for COVID-19 Benzinga
07:30AM	Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19 GlobeNewswire
Jun-01-21 07:30AM	Adamis Pharmaceuticals Provides Business Update GlobeNewswire
May-28-21 04:04PM	Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ GlobeNewswire
May-26-21 03:00PM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors Business Wire
11:30AM	The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors Business Wire
May-25-21 07:42PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors Business Wire -9.40%
02:12PM	Investor Alert: Berman Tabacco Investigates Potential Securities Law Violations By Adamis Pharmaceuticals Corporation (ADMP) In Connection With U.S. Attorney's Criminal Investigation Newsfile
May-17-21 04:05PM	Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call GlobeNewswire +7.06%
03:15PM	Adamis Pharmaceuticals Corp. to Host Earnings Call ACCESSWIRE
07:30AM	Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose GlobeNewswire
May-12-21 07:30AM	Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update GlobeNewswire
Apr-15-21 04:39PM	Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update GlobeNewswire -7.02%
Apr-13-21 04:03PM	Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update GlobeNewswire
Apr-12-21 10:28AM	Adamis Pharma To Resubmit Zimhi US Application For Opioid Overdose Soon Benzinga
07:00AM	Adamis Pharmaceuticals Provides an Update on ZIMHI GlobeNewswire
Mar-22-21 12:30PM	Will Adamis Pharmaceuticals (ADMP) Report Negative Q4 Earnings? What You Should Know Zacks
Mar-15-21 09:00AM	Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model GlobeNewswire +8.65%
Feb-22-21 09:00AM	Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19 GlobeNewswire
Feb-17-21 12:00PM	Adamis Pharma Shares Fall Despite US Patent Covering Naloxone Benzinga -5.10%
09:00AM	Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate GlobeNewswire
Feb-02-21 04:05PM	Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-29-21 09:00AM	Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -17.86%
Jan-28-21 04:01PM	Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
09:00AM	Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients GlobeNewswire
Jan-26-21 09:00AM	Adamis Pharmaceuticals Provides Update On Its US Compounding Business GlobeNewswire
Jan-22-21 10:47AM	FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher Today InvestorPlace +40.94%
09:59AM	ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shares Rocket Again InvestorPlace
Jan-21-21 06:39PM	Adamis COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: Analyst TipRanks -11.19%
04:05PM	SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products GlobeNewswire
01:27PM	Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar Zacks
10:02AM	Looking Into Adamis Pharmaceuticals's Return On Capital Employed Benzinga
08:05AM	The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga
Jan-20-21 01:06PM	Adamis Soars After Submitting Covid Drug to FDA TheStreet.com +77.64%
09:00AM	Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 GlobeNewswire
Jan-08-21 08:30AM	Adamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% Higher Zacks
Dec-01-20 09:00AM	Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter GlobeNewswire +21.88%
Nov-18-20 12:24PM	Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS Zacks
Nov-16-20 11:55AM	Why Adamis Pharmaceuticals Stock Is Trading Lower Today Benzinga -41.22%
06:45AM	Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI GlobeNewswire
Nov-09-20 06:35PM	Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:11PM	Adamis Pharmaceuticals: Q3 Earnings Insights Benzinga
04:30PM	Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update GlobeNewswire
03:15PM	Adamis Pharmaceuticals Corp. to Host Earnings Call ACCESSWIRE
Nov-05-20 09:00AM	Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update GlobeNewswire
Nov-03-20 12:30PM	Will Adamis Pharmaceuticals (ADMP) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-12-20 10:24AM	Looking Into Adamis Pharmaceuticals's Return On Capital Employed Benzinga
Sep-18-20 09:00AM	Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -9.41%
Sep-17-20 04:05PM	Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Sep-16-20 09:23AM	New Strong Sell Stocks for September 16th Zacks
Sep-03-20 04:05PM	Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders GlobeNewswire +7.27%
Aug-25-20 09:00AM	Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals GlobeNewswire
Aug-21-20 09:00AM	Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders GlobeNewswire
Aug-17-20 05:55PM	Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:40PM	Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update GlobeNewswire
Aug-14-20 09:00AM	Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19 GlobeNewswire -6.86%
Aug-06-20 12:30PM	Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Aug-05-20 04:05PM	Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement GlobeNewswire
Jul-23-20 09:00AM	Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? Zacks
Jul-01-20 09:00AM	Adamis Pharmaceuticals Provides Update on SYMJEPI Products GlobeNewswire
Jun-18-20 09:00AM	Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose GlobeNewswire -5.12%
Jun-15-20 09:00AM	Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19 GlobeNewswire +7.63%
May-27-20 09:00AM	Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone GlobeNewswire
May-25-20 10:37AM	Edited Transcript of ADMP earnings conference call or presentation 18-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-18-20 04:35PM	Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update GlobeNewswire +6.90%
09:00AM	Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA GlobeNewswire
May-15-20 09:00AM	Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update GlobeNewswire
May-12-20 08:06AM	The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
May-11-20 08:35PM	Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products GlobeNewswire
Apr-29-20 12:00PM	Adamis (ADMP) Moves to Strong Buy: Rationale Behind the Upgrade Zacks +8.05%
Apr-23-20 09:00AM	Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys GlobeNewswire +5.09%
Apr-21-20 09:00AM	Adamis Pharmaceuticals Announces Production of Additional Drugs by its US Compounding Subsidiary to Aid in the COVID-19 Pandemic GlobeNewswire
Apr-15-20 04:05PM	Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program GlobeNewswire
Apr-01-20 09:00AM	Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic GlobeNewswire +17.10%
Mar-30-20 04:40PM	Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update GlobeNewswire
Feb-21-20 09:15AM	Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering GlobeNewswire -8.04%
Feb-19-20 09:00AM	Adamis Pharmaceuticals Provides Update Regarding ZIMHI GlobeNewswire -9.47%
Jan-03-20 09:31PM	Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMT Thomson Reuters StreetEvents +10.91%

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marguglio David J.	SVP and Chief Business Officer	Nov 20	Sale	0.40	35,000	14,000	287,264	Nov 24 04:29 PM
Hopkins Robert O	Chief Financial Officer	Nov 20	Sale	0.41	35,000	14,182	254,810	Nov 24 04:26 PM
Moss Ronald B.	Chief Medical Officer	Nov 18	Sale	0.41	8,532	3,465	231,752	Nov 20 04:38 PM
Hopkins Robert O	Chief Financial Officer	Nov 18	Sale	0.41	7,229	2,936	289,810	Nov 20 04:34 PM
CARLO DENNIS J PHD	President & CEO	Nov 18	Sale	0.41	10,665	4,331	316,405	Nov 20 04:33 PM
Daniels Karen K.	VP of Operations	Nov 18	Sale	0.41	5,333	2,166	149,242	Nov 20 04:32 PM
Marguglio David J.	SVP and Chief Business Officer	Nov 18	Sale	0.41	8,532	3,465	322,264	Nov 20 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience